Noxopharm Ltd has released a press release.
Veyonda Showing Potential to Prevent Cytokine Storm
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Noxopharm
- Noxopharm Files Septic Shock Treatment Patent for Veyonda®
- Veyonda Patent Lodged for Major Septic Shock Opportunity
- Noxopharm IONIC Immuno-Oncology Trial Commences
- NOXCOVID Trial Advances to Final Stage
- Noxopharm Receives A$4.59M Federal Gov R&D Tax Rebate
Later from Noxopharm
- March Quarterly Activities Report and Appendix 4C
- Clinical Data Shows Noxopharm’s Veyonda® May Prevent Cytokine Storm
- Publications Positive Review of Veyonda in Chemotherapy
- Veyonda FDA Approved Trial to Commence
- Veyonda to Begin First-Line Sarcoma Treatment Testing
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm